The concern of generic rivalry has consistently loomed over copyright’s famous drug, PDE5 Inhibitor, raising questions about the future of related medicinal investments. While early periods saw substantial gains, the intellectual property expiration has created the door for discounted alternatives, likely reducing profitability and presenting a r